Bexagliflozin for T2DM
Connect2Clinic
An end-to-end Practice Management Platform that makes your In-Clinic & Online practice seamless!
Bexagliflozin (BRENZAVVY?) is an orally administered medication developed by TheracosBio for the treatment of type 2 diabetes (T2D) and essential hypertension. It is a potent inhibitor of sodium-glucose transporter 2 (SGLT-2). In January 2023, it received its first approval in the USA as an adjunct to diet and exercise to improve glycemic control in adults with T2D. However, bexagliflozin is contraindicated in patients on dialysis and is not recommended for patients with type 1 diabetes or with a low estimated glomerular filtration rate. In addition to its approved use in T2D, bexagliflozin is currently undergoing clinical development for the treatment of essential hypertension in the USA. This article provides an overview of the development milestones of bexagliflozin that led to its first approval for the treatment of T2D.
Read full article:
https://mu.connect2clinic.com/doctor/description/med-of-the-day/cb8caaae-43fc-4dee-b5c0-61f99613cb1b